Animal Aid

Man or Mouse


  • 1. Mukerjee M. Speaking for the Animals. Scientific American Aug 2004. p. 96.
  • 2. Hollinger S and Hepler JR. (2002) Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev 54(3):527-59.
  • 3. Behr R and Weinbauer GF. (2001) cAMP response element modulator (CREM): an essential factor for spermatogenesis in primates? Int J Androl 24(3):126-35.
  • 4. Dyck MK, Lacroix D, Pothier F, Sirard MA (2003) Making recombinant proteins in animals--different systems, different applications. Trends Biotechnol 21(9):394-9.
  • 5. Canadian Council on Animal Care (CCAC) guidelines on Transgenic Animals. (1997).
  • 6. Munk C, Lohler J, Prassolov V Just L, Stockschlader M and Stodking C. Amphoteric murine leukemia viruses induce spongiform encephalo-myelopathy PNAS 1997: 94: 5837-5842.
  • 7. Cornetta K, Morgan RA, Anderson WF. Safety issues related to retroviral-mediated gene transfer in humans. Human Gene Ther. 1991; 2(1):5-14.
  • 8. Gunter KC, Khan AS, Noguchi P The safety of retroviral vectors. Human Gene Ther. 1993; 4(5):643.
  • 9. Temin HM. Safety considerations in somatic gene-therapy of human-disease with retrovirus vectors. Hum Gene Ther. 1990; 1(2):111-123.
  • 10. Murphy D, Bishop A, Rindi G, Murphy MN, Stamp GW, Hanson J, Polak JM, Hogan B. (1987) Mice transgenic for a vasopressin-SV40 hybrid oncogene develop tumors of the endocrine pancreas and the anterior pituitary A possible model for human multiple endocrine neoplasia type 1. Am J Pathol;129(3):552-66.
  • 11. Palmiter RD and Brinster RL. (1986) Germ-line transformation of mice. Annu Rev Genet;20:465-99.
  • 12. Dean RG. (1998) Testing promoter/gene constructs for transgenic animals. University of Georgia Animal and Dairy Science, annual report, pp104-108.
  • 13. Rink L and Wenzel BE (1996) Transgenic mice models in autoimmunity - discussion. Exp Clin Endocrinol Diabetes 104 Suppl 3:46-8. Review.
  • 14. Van der Meer M, Baumans V Hofhuis FM et al. (2001) Consequences of gene targeting procedures for behavioural responses and morphological development of newborn mice. Transgenic Research 10;399-408.
  • 15. Shuldiner AR (1996) Transgenic animals. N Engl J Med. 334(10):653-5. Review.
  • 16. Galli-Taliadoros LA, Sedgwick JD, Wood SA, Korner H (1995) Gene knock-out technology: a methodological overview for the interested novice. J Immunol Methods 181(1):1-15. Review.
  • 17. Bradley A, Evans M, Kaufman MH, Robertson E (1984) Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. Nature 309(5965):255-6.
  • 18. Humpherys D, Eggan K, Akutsu H et al. (2001) Epigenetic instability in ES cells and cloned mice. Science 293(5527):95-7.
  • 19. Smith K and Spadafora C (2005) Sperm-mediated gene transfer: applications and implications. Bioessays 27(5):551-62.20. Pagan Westphal S (2002) Designer animals made easy. New Scientist 2336;6-7.
  • 20. Pagan Westphal S (2002) Designer animals made easy New Scientist 2336;6-7.
  • 21. Maione B, Lavitrano M, Spadafora C, Kiessling AA (1998) Sperm-mediated gene transfer in mice. Mol Reprod Dev;50(4):406-9.
  • 22. Zani M, Lavitrano M, French D, Lulli V (1995) The mechanism of binding of exogenous DNA to sperm cells: factors controlling the DNA uptake. Exp Cell Res. 1995; 217(1):57.
  • 23. Smith KR (2004) Gene Therapy: The Potential Applicability of Gene Transfer Technology to the Human Germline. Int. J. Med. Sci. 2004 1(2): 76-91.
  • 24. Nolan PM, Peters J, Strivens M et al. (2000) A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse. Nat Genet;25(4):440-3.
  • 25. Nolan PM, Peters J, Vizor L et al. (2000) Implementation of a large-scale ENU muta genesis program: towards increasing the mouse mutant resource. Mamm Genome;11(7):500-6.
  • 26. Hrabe de Angelis MH, Flaswinkel H, Fuchs H et al. (2000) Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nat Genet;25(4):444-7.
  • 27. Jackson IJ (2001) Mouse mutagenesis on target. Nat Genet;28(3):198-200.
  • 28. Goldowitz D, Frankel WN, Takahashi JS et al. (2004) Large-scale mutagenesis of the mouse to understand the genetic bases of nervous system structure and function. Brain Res Mol Brain Res;132(2):105-15.
  • 29. Ohl F and Keck ME (2003) Behavioural screening in mutagenised mice--in search for novel animal models of psychiatric disorders. Eur J Pharmacol;480(1-3):219-28.
  • 30. Keays DA and Nolan PM (2003) N-ethyl-N-nitrosourea mouse mutants in the dissection of behavioural and psychiatric disorders. Eur J Pharmacol;480(1-3):205-17.
  • 31. Nishimura I, Drake TA, Lusis AJ et al. (2003) ENU large-scale mutagenesis and quantitative trait linkage (QTL) analysis in mice: novel technologies for searching polygenetic determinants of craniofacial abnormalities. Crit Rev Oral Biol Med;14(5):320-30.
  • 32. Thaung C, West K, Clark BJ et al. (2002) Novel ENU-induced eye mutations in the mouse: models for human eye disease. Hum Mol Genet;11(7):755-67.
  • 33. Nolan PM, Hugill A, Cox RD (2002) ENU mutagenesis in the mouse: application to human genetic disease. Brief Funct Genomic Proteomic;1(3):278-89.
  • 34. Abbott A (2000) A mutant mouse menagerie. Nature 406;559.
  • 35. Abbott A (2002) Geneticists lay plans for rationalized rodents. Nature 417;211.
  • 36. Jenkins ES, Gray S, Combes RD (2001) Mutagenesis screens: can they be justified? Altern Lab Anim;29(1):63-8.
  • 37. Mepham TB, Combes RD, Balls M et al. (1998) The use of transgenic animals in the European Union:the report and recommendations of ECVAM workshop 29. ATLA 26;21-43.
  • 38. Petters RM and Sommer JR (2000) Transgenic animals as models for human disease. Transgenic Res 9(4-5):347-51; discussion 345-6.
  • 39. Snouwaert JN, Brigman KK, Latour AM et al. (1992) An animal model for cystic fibrosis made by gene targeting. Science. 1992;257(5073):1083-8.
  • 40. Barinaga M (1992) Knockout mice offer first animal model for CF. Science;257 (5073):1046-7.
  • 41. Wilson JM and Collins FS (1992) Cystic fibrosis. More from the modellers. Nature; 359(6392):195-6.
  • 42. Dorin JR, Dickinson P Alton EW et al. (1992) Cystic fibrosis in the mouse by targeted insertional mutagenesis. Nature;359(6392):211-5.
  • 43. Ratcliff R, Evans MJ, Cuthbert AW et al. (1993) Production of a severe cystic fibrosis mutation in mice by gene targeting. Nature Genetics 4, 35 - 41.
  • 44. Ameen N, Alexis J, Salas P (2000) Cellular localization of the cystic fibrosis transmembrane conductance regulator in mouse intestinal tract. Histochem Cell Biol;114: 69-75.
  • 45. Hardcastle J, Harwood MD, Taylor CJ (2004) Small intestinal glucose absorption in cystic fibrosis: a study in human and transgenic DeltaF508 cystic fibrosis mouse tissues. J Pharm Pharmacol;56: 329-38.
  • 46. Coates SW Jr, Hogenauer C, Santa Ana CA et al. (2004) Inhibition of neutral sodium absorption by a prostaglandin analogue in patients with cystic fibrosis. Gastroenterology;127: 65-72.
  • 47. Santis G and Geddes D (1994) Recent advances in cystic fibrosis. Postgrad Med J; 70: 247 - 251.
  • 48. Engelhardt JF Yankaskas JR, Ernst SA et al. (1992) Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet 2: 240-8.
  • 49. Pack RJ, Al-Ugaily LH, Morris G, Widdicombe JG. (1980) The distribution and structure of cells in the tracheal epithelium of the mouse. Cell Tissue Res 208: 65-84.
  • 50. Kelley KA, Stamm S, Kozak CA. (1992) Expression and chromosome localization of the murine cystic fibrosis transmembrane conductance regulator. Genomics 13: 381-8.
  • 51. Rogers DF, Alton EW, Dewar A et al. (1990) Tracheal potential difference in the reserpine and isoproterenol rat models of cystic fibrosis. Exp Lung Res;16:661-670.
  • 52. Pier GB, Small GJ, Warren HB (1990) Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infection. Science;249:537-540.
  • 53. Koller BH, Kim HS, Latour AM et al. (1991) Toward an animal model of cystic fibrosis: Targeted interruption of exon 10 of the cystic fibrosis transmembrane regulator gene in embryonic stem cells. Proc Natl Acad Sci USA;88:10730-10734.
  • 54. Rosenfeld MA, Yoshimura K, Trapnell BC et al. (1992) In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68(1);143-155.
  • 55. Kessler WR and Andersen DH (1951) Heat prostration in fibrocystic disease of the pancreas and other conditions. Pediatrics 8(5): 648-656.
  • 56. Di Sant' Agnese PA, Darling RC, Perera GA, Shea E (1953) Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; Clinical significance and relationship to the disease. Pediatrics 12(5): 549-563.
  • 57. Yamaya M, Finkbeiner WE, Widdicombe JH (1991) Altered ion transport by tracheal glands in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol; 261: 491 - 494.
  • 58. Cozens AL, Yezzi MJ, Chin L et al. (1992) Characterization of Immortal Cystic Fibrosis Tracheobronchial Gland Epithelial Cells. PNAS 89: 5171-5175.
  • 59. Clarke LL, Grubb BR, Yankaskas JR et al. (1994) Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in Cftr(-/-) mice. Proc Natl Acad Sci USA 91:479-483
  • 60. Rozmahel R, Wilschanski M, Matin A et al. (1996) Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet 12:280-287.
  • 61. Bronsveld I, Mekus F, Bijman J et al. (2001) Chloride conductance and genetic back ground modulate the cystic fibrosis phenotype of Delta-F508 homozygous twins and siblings. J Clin Invest 108: 1705-15.
  • 62. Egan ME, Pearson M, Weiner SA et al. (2004) Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304: 600-2.
  • 63. Song Y Sonawane ND, Salinas D et al. (2004) Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models. J Biol Chem 279(39):40629-33. Epub 2004 Jul 26.
  • 64. Hyde SC, Gill DR, Higgins CF et al. (1993) Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy Nature 362: 250 255.
  • 65. Alton EW, Middleton PG, Caplen NJ et al. (1993) Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mice. Nat Genet 5: 135 142.
  • 66. Griesenbach U, Geddes DM, Alton EW. (2003) Update on gene therapy for cystic fibrosis. Curr Opin Mol Ther 5: 489-94.
  • 67. Li Z and Engelhardt JF. (2003) Progress toward generating a ferret model of cystic fibrosis by somatic cell nuclear transfer. Reprod Biol Endocrinol 1(1):83.
  • 68. Williams SH, Sahota V Palmai-Pallag T et al. (2003) Evaluation of gene targeting by homologous recombination in ovine somatic cells. Mol Reprod Dev 66(2):115-25.
  • 69. Flotte TR, Zeitlin PL, Reynolds TC (2003) Phase I trial of intranasal and endo bronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 14(11):1079-88.
  • 70. Coates AL and Bush A. (2003) Basic science research vs. clinical research in cystic fibrosis: Has the pendulum swung too far? Pediatr Pulmonol 36: 175-7.
  • 71. Shak S, Capon DJ, Hellmiss R et al. (1990) Recombinant Human DNase I Reduces the Viscosity of Cystic Fibrosis Sputum. Proc Natl Acad Sci USA 87: 9188-9192.
  • 72. Hubbard RC, McElvaney NG, Birrer P et al. (1992) A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med;326(12):812-5.
  • 73. Zabner J, Seiler MP Launspach JL et al. (2000) The osmolyte xylitol reduces the salt concentration of airway surface liquid and may enhance bacterial killing. Proc Natl Acad Sci USA 97: 11614-11619.
  • 74. Cystic Fibrosis Foundation Annual Report, 2003. 2003%20Annual%20Report.pdf
  • 75. de Rijk MC, Launer LJ, Berger K et al. (2000) Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54(11 Suppl 5):S21-3.
  • 76. Kitada T Asakawa S, Hattori N et al. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676):605-8.
  • 77. Kruger R, Kuhn W, Muller T et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18(2):106-8
  • 78. Kruger R, Eberhardt O, Riess O, Schulz JB (2002) Parkinson's disease: one biochemical pathway to fit all genes? Trends Mol Med 8(5):236-40.
  • 79. Polymeropoulos MH, Lavedan C, Leroy E et al. (1997) Mutation in the alpha-synucle in gene identified in families with Parkinson's disease. Science 276(5321):2045-7.
  • 80. Bonifati V Rizzu P van Baren MJ et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299(5604): 256-9. Epub 2002 Nov 21.
  • 81. van Duijn CM, Dekker MC, Bonifati V et al. (2001) Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 69(3):629-34. Epub 2001 Jul 2.
  • 82. Foltynie T Sawcer S, Brayne C, Barker RA (2002) The genetic basis of Parkinson's disease. J Neurol Neurosurg Psychiatry 73(4):363-70.
  • 83. Gwinn-Hardy K, Farrer M (2002) Parkinson's genetics: an embarrassment of riches. Ann Neurol 51(1):7-8.
  • 84. Abeliovich A, Schmitz Y Farinas I et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25(1):239-52.
  • 85. Beal MF (2001) Experimental models of Parkinson's disease. Nat Rev Neurosci 2(5):325-34.
  • 86. Vila M, Wu DC, Przedborski S (2001) Engineered modeling and the secrets of Parkinson's disease. Trends Neurosci 24(11 Suppl):S49-55.
  • 87. Masliah E, Rockenstein E, Veinbergs I et al. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science;287(5456):1265-9.
  • 88. Zhou QY Quaife CJ, Palmiter RD (1995) Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature 374(6523):640-3.
  • 89. Zhou QY Palmiter RD (1995) Dopamine-deficient mice are severely hypoactive adipsic, and aphagic. Cell 83(7):1197-209.
  • 90. Kirik D, Rosenblad C, Burger C (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22(7):2780-91.
  • 91. Klein RL, King MA, Hamby ME, Meyer EM (2002) Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum Gene Ther 13(5):605-12.
  • 92. Goldberg MS, Palacino JJ, Meloni EG, Shen J (2002) Generation and characterisation of parkin knockout mice. Program 118.1 Washington DC: Society for Neuroscience.
  • 93. Goedert M (2001) Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2(7):492-501.
  • 94. Linazasoro G (2004) Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. Mov Disord 19(7):743-54.
  • 95. Roep BO and Atkinson M (2004) Animal models have little to teach us about type 1 diabetes: 1. In support of this proposal. Diabetologia;47(10):1650-6. Epub 2004 Oct 13.
  • 96. Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172(5):2731-8.
  • 97. Lohmann T (1998) Limitations of animal models for studying type 1 diabetes. Diabetes Metab Rev 14(2):192
  • 98. Hanson MS, Cetkovic-Cvrlje M, Ramiya VK (1996) Quantitative thresholds of MHC class II I-E expressed on hemopoietically derived antigen-presenting cells in transgenic NOD/Lt mice determine level of diabetes resistance and indicate mechanism of protection. J Immunol 157(3):1279-87.
  • 99. Schultz C, Hubbard GB, Tredici KD (2001) Tau pathology in neurons and glial cells of aged baboons. Adv Exp Med Biol 487:59-69.
  • 100. van Leuven F (2000) Single and multiple transgenic mice as models for Alzheimer's disease. Prog Neurobiol 61(3):305-12.
  • 101. St George-Hyslop PH and Westaway DA (1999) Alzheimer's disease: Antibody clears senile plaques. Nature 400, 116-117.
  • 102. Hardy J and Israel A (1999) Alzheimer's disease. In search of gamma-secretase. Nature 398(6727):466-7.
  • 103. Wolfe MS, Xia W, Ostaszewski BL et al. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and -secretase activity. Nature 398, 513 - 517.
  • 104. St George-Hyslop PH (2000) Piecing together Alzheimer's. Scientific American, Dec. 2000; p82.
  • 105. Marwick C (2000) Promising Vaccine Treatment for Alzheimer Disease Found. JAMA 284:1503-1505.
  • 106. Yamanaka S, Johnson MD, Grinberg A et al. (1994) Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. Proc Natl Acad Sci U S A 91(21):9975-9.
  • 107. Huang JQ, Trasler JM, Igdoura S et al. (1997) Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Hum Mol Genet 6(11):1879-85.
  • 108. Kuehn MR, Bradley A, Robertson EJ, Evans MJ (1987) A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice. Nature 326(6110):295-8.
  • 109. Wu CL and Melton DW (1993) Production of a model for Lesch-Nyhan syndrome in hypoxanthine phosphoribosyltransferase-deficient mice. Nat Genet 3(3):235-40.
  • 110. Meijers JM, Swaen GM, Bloemen LJ (1997) The predictive value of animal data in human cancer risk assessment. Regul Toxicol Pharmacol 25(2):94-102.
  • 111. Gottmann E, Kramer S, Pfahringer B, Helma C (2001) Data quality in predictive toxicology: reproducibility of rodent carcinogenicity experiments. Environ Health Perspect 109(5):509-14.
  • 112. Robinson DE and MacDonald JS (2001) Background and framework for ILSI's col laborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute. Toxicol Pathol 29 Suppl:13-9.
  • 113. Pettit SD (2001) Panel discussion on the application of alternative models to cancer risk assessment. Toxicol Pathol 29 Suppl:191-5.
  • 114. Rice JM (2004) Causation of nervous system tumors in children: insights from traditional and genetically engineered animal models. Toxicol Appl Pharmacol 199(2):175-91.
  • 115. Miyagawa S, Murakami H, Takahagi Y et al. (2001) Remodeling of the major pig xenoantigen by N-acetylglucosaminyltransferase III in transgenic pig. J Biol Chem 276(42):39310-9. Epub 2001 Aug
  • 116. Byrne GW, McCurry KR, Martin MJ (1997) Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 63(1):149-55.
  • 117. Kulick DM, Salerno CT Dalmasso AP et al. (2000) Transgenic swine lungs expressing human CD59 are protected from injury in a pig-to-human model of xeno transplantation. J Thorac Cardiovasc Surg 119(4 Pt 1):690-9.
  • 118. Butler D (2002) Xenotransplant experts express caution over knockout piglets. Nature 415, 103-104.
  • 119. Chua KB (2003) Nipah virus outbreak in Malaysia. J Clin Virol 26(3):265-75.
  • 120. Day M (1997) Pigs caused Great War flu deaths. New Scientist 29 March 1997, issue 2075, p20.
  • 121. Weiss RA (1998) Transgenic pigs and virus adaptation. Nature 391(6665):327-8.
  • 122. Yoo D and Giulivi A (2000) Xenotransplantation and the potential risk of xenogeneic transmission of porcine viruses. Can J Vet Res 64(4):193-203.
  • 123. Allan J (1997) Silk purse or sow's ear. Nat Med 3(3):275-6.
  • 124. Crick SJ, Sheppard MN, Ho SY et al. (1998) Anatomy of the pig heart: comparisons with normal human cardiac structure. J Anat 193 ( Pt 1):105-19.
  • 125. Langley Dr. G. and Joyce D'Silva (1998) Animal Organs in Humans: Uncalculated Risks and Unanswered Questions. ISBN: 1 870356 21 7. British Union for the Abolition of Vivisection and Compassion in World Farming.
  • 126. Perin EC, Dohmann HF Borojevic R et al. (2004) Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy Circulation 110(11 Suppl 1):II213-8.
  • 127. Young MW, Meade H, Curling JM et al. (1998) Production of recombinant antibodies in the milk of transgenic animals. Res Immunol 149(6):609-10.
  • 128. Rohricht P (1999) Transgenic Protein Production. BioPharm; March 01, 1999.
  • 129. Wall RJ (1999) Biotechnology for the production of modified and innovative animal products: transgenic livestock bioreactors. Livestock Production Science 59(2-3); 243-255.
  • 130. Meade H and Ziomek C (1998) Urine as a substitute for milk? Nat Biotechnol 16(1):21-2.
  • 131. Dyck MK, Gagne D, Ouellet M (1999) Seminal vesicle production and secretion of growth hormone into seminal fluid. Nat Biotechnol 17(11):1087-90.
  • 132. Stromqvist M, Houdebine M, Andersson JO et al. (1997) Recombinant human extra cellular superoxide dismutase produced in milk of transgenic rabbits. Transgenic Res 6(4):271-8.
  • 133. Meade M et al. (1999) Expression of recombinant proteins in the milk of transgenic animals; in 'Gene Expression Systems: Using Nature for the Art of Expression.' Eds. Fernandez and Hoeffler. Academic Press.
  • 134. Houdebine LM (2000) Transgenic animal bioreactors. Transgenic Res 9(4-5):305-20.
  • 135. Osborne L (2000) Fuzzy little test tubes. New York Times magazine, July 29th 2000.
  • 136. Green JE, Desai KV, Ye Y Kavanaugh C, Calvo A, Huh JI. (2004) Application of gene expression profiling for validating models of human breast cancer. Toxicologic Pathology. 32 Suppl 1:84-9


Amino Acid
The building blocks of polypeptides and proteins.

An early stage embryo (typically a few days after fertilisation), taking the form of a hollow ball of cells.

The smallest unit of living matter that can function independently. Microscopic fluid compartments containing a concentrated solution of chemicals, along with various structures that help the cell to stay alive, replicate and perform its necessary functions.

An individual organism whose constituent cells do not have an identical genetic constitution.

A long and continuous thread of DNA containing many genes.

An individual grown from a single cell of another, and genetically virtually identical to it

The process whereby identical individual molecules (e.g. DNA) or virtually identical organisms (clones) are produced.

Deoxyribonucleic acid. The chemical constituent of chromosomes, made up of long chains of four different 'nucleotides,' in the form a double helix

Embryonic Stem Cell
Cells from an early-stage developing embryo, that are able to differentiate into any type of specialised cell (e.g. liver, muscle, nerve etc)

Any protein that affects the rate at which a biochemical reaction is carried out

A specific section of DNA on a chromosome, coding for a particular chain of amino-acids known as a 'polypeptide.' Can be 'Structural' or 'Regulatory ' . Genetically Modified Animals Animals whose DNA has been artificially manipulated. This includes clones, mutants and transgenic animals.

The entire genetic complement of a living organism.

In Vitro
Literally, 'in glass.' In research, this term refers to experiments conducted in test-tubes and plastic flasks etc., rather than 'In Vivo' or in living animals.

Organisms with one or more genes disabled via the insertion and/or deletion of segments of 'foreign' DNA.

Organisms containing a fully functioning 'foreign' gene

The process of causing genetic changes in individuals that alter or disrupt gene function.

One of the four molecules that form the basic structural units of DNA.

Defined and bounded region of a cell, containing the cell's genetic material in the form of chromosomes made from DNA.

The observable properties of an organism resulting from the function of its genes, and their interaction with the environment.

A chain of amino-acids linked by 'peptide' chemical bonds (hence the name), encoded by a gene. See 'Protein.'

Composed of a chain (or chains) of amino-acids, i.e. one or more polypeptides, with a defined '3D' complex structure that defines its biological function.

Regulatory Gene
Regulatory genes control the expression of structural and other regulatory genes, increasing and decreasing their levels of activity or turning them 'on' or 'off' completely.

Ribonucleic acid. Similar in structure, but not identical to, DNA. It is responsible for many biological functions, including a role as an intermediary in the production of proteins from DNA.

Structural Gene
Structural genes code for proteins that 'make up' our bodies; that build our cells and organs, and that form enzymes that carry out chemical reactions vital for life. See also 'Regulatory genes.'

The first part of 'gene expression.' This is the process whereby an RNA 'copy' of DNA is produced, acting as an intermediate molecule in the production of a polypeptide/protein.

A 'foreign' gene introduced into a new 'host' organism.

The process whereby a foreign 'transgene' is assembled and introduced into a new 'host' organism.

The second main part of 'gene expression,' after transcription.This is the process whereby an RNA copy of a gene is used as a template to produce a polypeptide/protein made from amino-acids.

A sub-microscopic infectious agent, composed of a protein 'coat' containing DNA or RNA, that can 'infect' living cells and reproduce inside them.

A process whereby organs from one species are transplanted into the bodies of another species, for example pig hearts into baboons.

Send this page to a friend

Read about how we treat your data: privacy policy.

© Copyright Animal Aid 2014